Theranostics: New hope for late stage prostate cancer patients
with an innovative UK-first treatment
Dr Yong Du, Clinical Director Theranostics; Julie Martin, Business Development Theranostics; Emma Spellman Head of Theranostics and Imaging UK and Dan McGowan, Research Physicist – Nuclear Medicine.
The first patients in the UK have now received an innovative theranostics
treatment for advanced prostate cancer at GenesisCare, giving new hope for men who have exhausted
other treatment options. The UK’s largest private cancer care provider, GenesisCare, announced today
that the service is now available at its centre in Windsor for the first time in the UK.